Results 1 to 10 of about 4,513 (159)

Adding aprepitant to palonosetron does not decrease carboplatin-induced nausea and vomiting in patients with gynecologic cancer [PDF]

Journal of Pharmaceutical Health Care and Sciences, 2021
Background Recently, aprepitant has been recommended in carboplatin-based regimens, but there are limited reports on the efficacy of administering aprepitant, palonosetron, and dexamethasone (DEX) in carboplatin-containing regimens.
Yuko Watanabe, Yoshitaka Saito, Takashi Mitamura, Yoh Takekuma, Mitsuru Sugawara   +4 more
doaj   +2 more sources

Utility of Aprepitant in the Management of Pediatric Patients with Cyclical Vomiting Syndrome [PDF]

Medicines
Introduction: Cyclical vomiting syndrome (CVS) is a recurrent debilitating illness characterized by intense episodes of nausea and emesis with widely varied pharmacological management across the country.
Aravind Thavamani, Sindhoosha Malay, Jasmine Khatana, Sujithra Velayuthan, Senthilkumar Sankararaman   +4 more
doaj   +2 more sources

Aprepitant versus Olanzapine in Patients of Breast Cancer on Adriamycin and Cyclophosphamide Regimen – Role in Effectiveness of Prevention of Nausea and Vomiting [PDF]

Acta Medica Lituanica
Background: Chemotherapy-induced nausea and vomiting (CINV) is a significant concern for patients undergoing highly emetogenic chemotherapy (HEC). This study compares the efficacy of aprepitant and olanzapine in preventing CINV in breast cancer patients
Indrani Devi Sarma, Sukainnya Buragohain, Joonmoni Lahon, Indrani Bhagawati, Neelakshi Mahanta, Dibyajyoti Saikia   +5 more
doaj   +2 more sources

Enhanced anti-angiogenic effects of aprepitant-loaded nanoparticles in human umbilical vein endothelial cells [PDF]

Scientific Reports
Recent advancements in cancer therapy have led to the development of novel nanoparticle-based drug delivery systems aimed at enhancing the efficacy of chemotherapeutic agents.
Elif Kaya-Tilki, Ahmet Alper Öztürk, Selin Engür-Öztürk, Miriş Dikmen   +3 more
doaj   +2 more sources

Enhanced efficacy of aprepitant-based triple prophylaxis in preventing postoperative nausea and vomiting following metabolic bariatric surgery: a single-center, retrospective cohort study [PDF]

Frontiers in Medicine
BackgroundMetabolic bariatric surgery (MBS) is associated with high risk of postoperative nausea and vomiting (PONV). We aimed to investigate the impact of aprepitant-based triple prophylaxis on PONV after MBS.MethodsWe reviewed a retrospective cohort of
Xiaodong Shan, Xiaodong Shan, Xiaodong Shan, Yidi Yang, Xiaoao Xiao, Mingchuang Zhang, Rui Chen, Qingqiu Huang, Yuanqing Gao, Xitai Sun, Xitai Sun   +10 more
doaj   +2 more sources

Comparison of aprepitant versus ondansetron for prevention of postoperative nausea and vomiting: A systematic review and meta-analysis with trial sequential analysis [PDF]

Indian Journal of Anaesthesia
Background and Aims: Postoperative nausea and vomiting (PONV) is a common complication after surgery. Preventing PONV in high-risk patients often requires a multimodal approach combining antiemetic drugs with diverse mechanisms.
Madhusudan P. Singh, Meenalotchini P. Gurunthalingam, Ayushee Gupta, Juhi Singh   +3 more
doaj   +2 more sources

Aprepitant inhibits the development and metastasis of gallbladder cancer via ROS and MAPK activation

BMC Cancer, 2023
Background Aprepitant, as a neurokinin-1 receptor (NK-1R) antagonist, originally applied for curing chemotherapy-induced nausea and vomiting, has been reported to have significant antitumor effect on several malignant tumors.
Xueyan Cao, Yang Yang, Wei Zhou, Yue Wang, Xue Wang, Xianxiu Ge, Fei Wang, Fangfang Zhou, Xueting Deng, Lin Miao   +9 more
doaj   +1 more source

The use of aprepitant in the first cycle of moderately emetogenic chemotherapy in patients with colorectal cancer: its preventive effect on chemotherapy-induced nausea and vomiting [PDF]

Korean Journal of Clinical Oncology, 2013
Purpose: There have been fever studies about the effectiveness of aprepitant in the first cycle of moderately emetogenic chemotherapy. The aim of this study was to determine whether aprepitant shows the effectiveness for prevention of chemotherapy ...
Jung Won Ryu, Sun Jin Park, Min-Su Park, Jin Seop Kim, Kil Yeon Lee   +4 more
doaj   +1 more source

The effect of aprepitant for the prevention of postoperative nausea and vomiting in patients undergoing gynecologic surgery with intravenous patient controlled analgesia using fentanyl: aprepitant plus ramosetron vs ramosetron alone [PDF]

Korean Journal of Anesthesiology, 2012
BackgroundThe purpose of this study was to evaluate the effect of an aprepitant, neurokinin-1(NK1) receptor antagonist, for reducing postoperative nausea and vomiting (PONV) for up to 24 hours in patients regarded as high risk undergoing gynecological ...
Se-Jin Lee, Su Myung Lee, Soon Im Kim, Si Young Ok, Sang Ho Kim, Sun-Young Park, Mun-Gyu Kim   +6 more
doaj   +1 more source

Design and Characterization of Phosphatidylcholine-Based Solid Dispersions of Aprepitant for Enhanced Solubility and Dissolution

Pharmaceutics, 2020
This study aimed to improve the solubility and dissolution of aprepitant, a drug with poor aqueous solubility, using a phosphatidylcholine (PC)-based solid dispersion system.
Sooho Yeo, Jieun An, Changhee Park, Dohyun Kim, Jaehwi Lee   +4 more
doaj   +1 more source